| Year |
Citation |
Score |
| 2005 |
Nestorov I, Zitnik R, Ludden T. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. Journal of Pharmacokinetics and Pharmacodynamics. 31: 463-90. PMID 16222785 DOI: 10.1007/S10928-005-5912-0 |
0.381 |
|
| 2003 |
Mu S, Ludden TM. Estimation of population pharmacokinetic parameters in the presence of non-compliance. Journal of Pharmacokinetics and Pharmacodynamics. 30: 53-81. PMID 12800807 DOI: 10.1023/A:1023297426153 |
0.455 |
|
| 2002 |
Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ. Population pharmacokinetic meta-analysis with efavirenz International Journal of Clinical Pharmacology and Therapeutics. 40: 507-519. PMID 12698988 |
0.318 |
|
| 2001 |
Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia Journal of Pharmacokinetics and Pharmacodynamics. 28: 555-575. PMID 11999292 DOI: 10.1023/A:1014412521191 |
0.353 |
|
| 1999 |
Mu S, Ludden TM. Estimation of patient compliance using a Bayesian approach Clinical Pharmacology and Therapeutics. 65: 185. |
0.387 |
|
| 1996 |
Sun H, Ette EI, Ludden TM. On the recording of sample times and parameter estimation from repeated measures. Pharmacokinetic data Journal of Pharmacokinetics and Biopharmaceutics. 24: 637-650. PMID 9300354 DOI: 10.1007/BF02353484 |
0.35 |
|
| 1990 |
Mangold DJ, Huelle BK, Miller MA, Geary RS, Sanchez-Barona DOT, Swynnerton NF, Fleckenstein L, Ludden TM. Pharmacokinetics and disposition of WR-1065 in the rhesus monkey Drug Metabolism and Disposition. 18: 281-287. PMID 1974187 |
0.332 |
|
| 1989 |
Graves NM, Ludden TM, Holmes GB, Fuerst RH, Leppik IE. Pharmacokinetics of felbamate, a novel antiepileptic drug: Application of mixed-effect modeling to clinical trials Pharmacotherapy. 9: 372-376. PMID 2694113 |
0.337 |
|
| 1987 |
Boucher BA, Rodman JH, Fabian TC, Cupit GC, Ludden TM, West ME, Ray MW. Disposition of phenytoin in critically ill trauma patients Clinical Pharmacy. 6: 881-887. PMID 3677565 |
0.32 |
|
| 1987 |
Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. European Journal of Clinical Pharmacology. 32: 141-8. PMID 3582477 DOI: 10.1007/BF00542186 |
0.311 |
|
| 1983 |
Taylor JW, Murphy MJ, Berg MJ, Perry PJ, Lyon LW, Ludden TM. Phenytoin dosage requirements and pharmacokinetic variables Clinical Pharmacy. 2: 253-257. PMID 6883953 |
0.325 |
|
| 1983 |
Hersh MR, Ludden TM, Kuhn JG, Knight WA. Pharmacokinetics of high dose melphalan. Investigational New Drugs. 1: 331-4. PMID 6678879 DOI: 10.1007/BF00177417 |
0.314 |
|
| 1983 |
Yuen GJ, Bell RD, Ludden TM. Phenytoin cumulation profiles Research Communications in Chemical Pathology and Pharmacology. 42: 355-368. PMID 6665297 |
0.333 |
|
| 1981 |
Ludden TM, McNay JL, Shepherd AM, Lin MS. Variability of plasma hydralazine concentrations in male hypertensive patients. Arthritis and Rheumatism. 24: 987-93. PMID 7284051 |
0.308 |
|
| 1979 |
Allen JP, Ludden TM, Burrow SR, Clementi WA, Stavchansky SA. Phenytoin cumulation kinetics Clinical Pharmacology and Therapeutics. 26: 445-448. PMID 487692 DOI: 10.1002/Cpt1979264445 |
0.302 |
|
| Show low-probability matches. |